AGAP2-AS1 May Promote the Occurrence and Development of Glioblastoma by Sponging miR-9-5p: Evidence From a ceRNA Network

Luo, Xiaobin; Tu, Tianqi; Zhong, Yali; Xu, Shangyi; Chen, Xiangzhou; Chen, Ligang; Yang, Fubing

doi:10.3389/fonc.2021.607989

Cited by 5 publications

(3 citation statements)

References 47 publications

(44 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In our study, we identified 20 prognostic lncRNAs and revealed that these prognosis-related lncRNAs were dysregulated in glioma. It was suggested that AGAP2-AS1 overexpression was an unfavorable prognostic factor in many carcinomas, such as lung carcinoma and glioma [27][28][29]. In GBM, AGAP2-AS1 has been identified as an oncogenic gene that regulates GBM cell motility and invasion.…”

Section: Discussionmentioning

confidence: 99%

Identification of Prognostic LncRNAs Subtypes Predicts Prognosis and Immune Microenvironment for Glioma

Chen

Peng

Teng

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Glioma is the most commonly occurring primary neuroepithelial neoplasm. Long noncoding RNAs (lncRNAs) are emerging as pivotal modulators of gene expression in the immune system and play critical roles in the growth, progression, and immune response of carcinomas. In this study, we performed univariate Cox regression analysis on survival data from TCGA and identified 20 prognostic lncRNAs. Moreover, we revealed that these prognosis-related lncRNAs (PRLnc) were dysregulated in glioma. Furthermore, we constructed a signature based on the expression levels of these prognosis-related lncRNAs based on 13 prognostic lncRNAs, including AGAP2-AS1, CYTOR, MIR155HG, LINC00634, HOTAIRM1, SNHG18, LINC01841, LINC01842, LINC01426, MIR9-3HG, TMEM220-AS1, LINC00641, LINC01270, and LINC01503. The Kaplan–Meier curves show that high-risk patients had a shorter survival time. Finally, the glioma samples were classified into 2 subgroups based on the median expression of prognosis-related lncRNAs in each sample. In summary, these findings suggest that PRLnc is associated with tumor-infiltrating immune cells in glioma and that subtype 2 patients may respond more positively to immunotherapy.

show abstract

Section: Discussionmentioning

confidence: 99%

Identification of Prognostic LncRNAs Subtypes Predicts Prognosis and Immune Microenvironment for Glioma

Chen

Peng

Teng

et al. 2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…MiR-100-5p downregulation in pancreatic ductal adenocarcinoma (PDAC) [ 47 ], oral squamous cell carcinoma [ 48 ], prostate cancer [ 49 , 50 ], lung cancer [ 51 ], bladder cancer [ 52 ], endometrial carcinoma [ 53 ] and breast cancer [ 54 , 55 , 56 ] contributes to tumor progression by regulating cell tumor proliferation, the response to therapy, migration, invasion or stemness. MiR-9 is also described as a negative regulator of tumor cell proliferation, invasion or drug resistance in pancreatic cancer cells [ 57 ], PDAC [ 47 ], hepatocellular carcinoma [ 58 ], gastric cancer [ 59 ], prostate cancer [ 60 ] or GBM [ 61 , 62 , 63 ]. The non-coding RNA let-7d can have different targets and effect in tumors [ 64 ].…”

Section: Discussionmentioning

confidence: 99%

The Activation of Mesenchymal Stem Cells by Glioblastoma Microvesicles Alters Their Exosomal Secretion of miR-100-5p, miR-9-5p and let-7d-5p

et al. 2022

View full text Add to dashboard Cite

Glioblastoma (GBM) is the most aggressive brain tumor, and despite initial response to chemo- and radio-therapy, the persistence of glioblastoma stem cells (GSCs) unfortunately always results in tumor recurrence. It is now largely admitted that tumor cells recruit normal cells, including mesenchymal stem cells (MSCs), and components of their environment, to participate in tumor progression, building up what is called the tumor microenvironment (TME). While growth factors and cytokines constitute essential messengers to pass on signals between tumor and TME, recent uncovering of extracellular vesicles (EVs), composed of microvesicles (MVs) and exosomes, opened new perspectives to define the modalities of this communication. In the GBM context particularly, we investigated what could be the nature of the EV exchange between GSCs and MSCs. We show that GSCs MVs can activate MSCs into cancer-associated fibroblasts (CAFs)-like cells, that subsequently increase their secretion of exosomes. Moreover, a significant decrease in anti-tumoral miR-100-5p, miR-9-5p and let-7d-5p was observed in these exosomes. This clearly suggests a miRNA-mediated GBM tumor promotion by MSCs exosomes, after their activation by GBM MVs.

show abstract

“…LncRNA AGAP2 antisense RNA 1 ( AGAP2-AS1 ), transcribed from a gene located at 12q14.1, a novel cancer-related lncRNA, was dysregulated in cancers ( 42 ). In GBM, lncRNA HOTAIRM1 ( 43 , 44 ) and AGAP2-AS1 ( 45 , 46 ), as oncogenic factors, promoted tumorigenesis, predicted a poor clinical outcome, and were potential biomarkers and therapeutic targets. Keratin 8 (KRT8), a major component of the intermediate filament cytoskeleton, promotes tumor progression and metastasis of various cancers ( 47 – 49 ).…”

Section: Discussionmentioning

confidence: 99%

Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma

Hou

et al. 2021

Front. Immunol.

View full text Add to dashboard Cite

BackgroundGlioblastoma multiforme (GBM) is extensively genetically and transcriptionally heterogeneous, which poses challenges for classification and management. Long noncoding RNAs (lncRNAs) play a critical role in the development and progression of GBM, especially in tumor-associated immune processes. Therefore, it is necessary to develop an immune-related lncRNAs (irlncRNAs) signature.MethodsUnivariate and multivariate Cox regression analyses were utilized to construct a prognostic model. GBM-specific CeRNA and PPI network was constructed to predict lncRNAs targets and evaluate the interactions of immune mRNAs translated proteins. GO and KEGG pathway analyses were used to show the biological functions and pathways of CeRNA network-related immunity genes. Consensus Cluster Plus analysis was used for GBM gene clustering. Then, we evaluated GBM subtype-specific prognostic values, clinical characteristics, genes and pathways, immune infiltration access single cell RNA-seq data, and chemotherapeutics efficacy. The hub genes were finally validated.ResultsA total of 17 prognostically related irlncRNAs were screened to build a prognostic model signature based on six key irlncRNAs. Based on GBM-specific CeRNAs and enrichment analysis, PLAU was predicted as a target of lncRNA-H19 and mainly enriched in the malignant related pathways. GBM subtype-A displayed the most favorable prognosis, high proportion of genes (IDH1, ATRX, and EGFR) mutation, chemoradiotherapy, and low risk and was characterized by low expression of four high-risk lncRNAs (H19, HOTAIRM1, AGAP2-AS1, and AC002456.1) and one mRNA KRT8. GSs with poor survival were mainly infiltrated by mesenchymal stem cells (MSCs) and astrocyte, and were more sensitive to gefitinib and roscovitine. Among GSs, three hub genes KRT8, NGFR, and TCEA3, were screened and validated to potentially play feasible oncogenic roles in GBM.ConclusionConstruction of lncRNAs risk model and identification of GBM subtypes based on 17 irlncRNAs, which suggesting that irlncRNAs had the promising potential for clinical immunotherapy of GBM.

show abstract

AGAP2-AS1 May Promote the Occurrence and Development of Glioblastoma by Sponging miR-9-5p: Evidence From a ceRNA Network

Cited by 5 publications

References 47 publications

Identification of Prognostic LncRNAs Subtypes Predicts Prognosis and Immune Microenvironment for Glioma

Identification of Prognostic LncRNAs Subtypes Predicts Prognosis and Immune Microenvironment for Glioma

The Activation of Mesenchymal Stem Cells by Glioblastoma Microvesicles Alters Their Exosomal Secretion of miR-100-5p, miR-9-5p and let-7d-5p

Identification of Immune-Related lncRNA Prognostic Signature and Molecular Subtypes for Glioblastoma

Contact Info

Product

Resources

About